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Abstract
Aims: A study of 222 candidate genes in type 2 diabetes reported association of variants in RAPGEF1, ENPP1, TP53, NRF1,
SLC2A2, SLC2A4 and FOXC2 with type 2 diabetes in 4,805 Finnish individuals. We aimed to replicate these associations in a
Danish case-control study and to substantiate any replicated associations in meta-analyses. Furthermore, we evaluated the
impact on diabetes-related intermediate traits in a population-based sample of middle-aged Danes.
Methods: We genotyped nine lead variants in the seven genes in 4,973 glucose-tolerant and 3,612 type 2 diabetes Danish
individuals. In meta-analyses we combined case-control data from the DIAGRAM+ Consortium (n=47,117) and the present
genotyping results. The quantitative trait studies involved 5,882 treatment-naive individuals from the Danish Inter99 study.
Results: None of the nine investigated variants were significantly associated with type 2 diabetes in the Danish samples.
However, for all nine variants the estimate of increase in type 2 diabetes risk was observed for the same allele as previously
reported. In a meta-analysis of published and online data including 55,521 Europeans the G-allele of rs1042522 in TP53
showed significant association with type 2 diabetes (OR=1.06 95% CI 1.02–1.11, p=0.0032). No substantial associations
with diabetes-related intermediary phenotypes were found.
Conclusion: The G-allele of TP53 rs1042522 is associated with an increased prevalence of type 2 diabetes in a combined
analysis of 55,521 Europeans.
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Introduction
Type 2 diabetes is a rapidly growing health problem worldwide.
Although the epidemic nature of the disease may be attributable
mainly to environmental factors leading to obesity, also genetic
factors predispose to the disease. Type 2 diabetes is characterized
by insulin resistance in skeletal muscle, liver and adipose tissue, in
combination with insufficient pancreatic beta-cell function, leading
to elevated levels of blood glucose.
In the past three years numerous genome-wide association
studies (GWAS) have identified common type 2 diabetes
susceptibility variants [1]. Although GWAS have proved superior
to candidate gene based approaches in the discovery of
susceptibility genes for complex diseases there may still be a need
for well-designed targeted evaluation of disease candidate genes. A
publication in 2008 used a complementary approach by
performing an in-depth, step-wise analysis of 222 candidate genes
likely to influence susceptibility to type 2 diabetes [2], selected by
applying CandidAtE Search And Rank (CAESAR), a text- and
data mining algorithm [3]. In a case-control study of 1,161 type 2
diabetic patients and 1,174 control subjects, 3,531 variants in these
222 genes were genotyped and after imputation of additional
variants, coverage of 99.9% of common HapMap variants was
achieved. Selected single-nucleotide polymorphisms (SNPs) were
genotyped in additional 1,211 type 2 diabetic cases and 1,259
control individuals. Of the investigated variants, 16 were
associated with type 2 diabetes at a 5% significance level in the
combined study sample [2]. The top ten type 2 diabetes variants
included variants in eight genes: RAPGEF1 rs4740283, ENPP1
rs2021966 and rs858341, NRF1 rs1882095, TP53 rs1042522,
SLC2A2 rs10513684 and rs5400, SLC2A4 rs222852, FOXC2
rs4843165, and PPARG.
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15813The variant in PPARG is a confirmed type 2 diabetes
polymorphism at genome-wide significance level [4], while the
rest are either novel putative type 2 diabetes susceptibility loci or
variants in genes previously associated with diabetes risk at a
conventional significance level. In the present report, we aimed at
replicating the top nine novel associations with type 2 diabetes in
seven loci in a Danish case-control study (excluding the previously
investigated PPARG variant) followed by a meta-analysis of our
data and reported association studies. Furthermore, we evaluated
the impact of these variants on diabetes-related intermediate traits
in the Inter99 cohort where study participants have been
characterized by an oral glucose tolerance test (OGTT) and
derived estimates of insulin release and insulin sensitivity.
Materials and Methods
Participants
The studies were approved by the regional Ethical Committees
and were in accordance with the principles of the Helsinki
Declaration. The nine variants were genotyped in 5,882
treatment-naive middle-aged individuals from the Inter99 cohort
and in additional Danish individuals totalling a case-control study
of 4,973 glucose-tolerant participants and 3,612 type 2 diabetic
cases. The total of 10,157 Danish individuals were ascertained
from four different study groups; 1) the Inter99 cohort which is a
randomized, non-pharmacological intervention study of randomly
ascertained middle-aged individuals for the prevention of ischemic
heart disease, conducted at the Research Centre for Prevention
and Health in Glostrup, Copenhagen (ClinicalTrials.gov ID-no:
NCT00289237) [5,6] (n=5,999); 2) type 2 diabetic patients from
the Danish Anglo-Danish-Dutch Study of Intensive Treatment in
People with Screen-Detected Diabetes in Primary Care (ADDI-
TION) study (ClinicalTrials.gov ID-no: NCT00237548) [7],
which is a population-based, high-risk screening and intervention
study for type 2 diabetes in general practice (n=1,583); 3) Type 2
diabetes patients and normal glucose tolerant subjects from a
randomly recruited group of unrelated middle-aged individuals
(n=562) examined at Steno Diabetes Center; and 4) unrelated
type 2 diabetic patients (n=2,013) sampled through the out-
patient clinic at Steno Diabetes Center. All participants in study
group 1 and 3 underwent a standard 75 g OGTT. Type 2 diabetes
and glucose tolerance status were defined according to the World
Health Organization 1999 criteria [8]. All study participants were
Danes by self-report and informed written consent was obtained
from all before participation. An overview of the clinical
characteristics of the four study groups is given in Table S2.
Description of the DIAGRAM+ study participants are described
in the primary study by Voight et al [9].
Biochemical and anthropometric measures
In all four study groups body weight and height were measured
in light indoor clothes and without shoes. BMI was defined as
weight in kilograms divided by height in meters squared (kg/m
2).
Waist circumference (cm) was measured with subjects in standing
position midway between the iliac crest and the lower costal
margin. Blood samples were drawn after a 12 h overnight fast.
Plasma glucose was analysed by a glucose oxidase method
(Granutest; Merck, Darmstadt, Germany). HbA1c was measured
by ion-exchange high-performance liquid chromatography (nor-
mal reference range: 4.1–6.4%) and serum insulin, excluding
des(31, 32) and intact proinsulin, was measured using an insulin kit
(AutoDELFIA, Perkin-Elmer/Wallac, Turku, Finland). Serum C-
peptide concentrations were measured by a time-resolved
fluoroimmunoassay (AutoDELFIA C-peptide kit; Perkin-Elmer/
Wallac). Serum triglyceride, total cholesterol and HDL-cholesterol
were analysed using enzymatic colorimetric methods (GPO-PAP
and CHOD-PAP, Roche Molecular Biochemicals, Basel, Swit-
zerland). Homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as described [10]. The OGTT-
derived indices of insulin sensitivity (BIGTT-SI) and beta-cell
function (BIGTT-acute insulin response (AIR)) were calculated as
reported [11].
Genotyping
Genotyping of the nine variants in 10,157 Danish individuals
was done using KASParH SNP genotyping (KBioscience, Herts,
UK). All genotyping success rates were .95% and error rates
were ,0.4% estimated from re-genotyping of 513 random
duplicate samples. Genotype distributions for all variants obeyed
Hardy-Weinberg equilibrium in the investigated study groups
(P.0.05).
Statistical analysis
The case-control study of type 2 diabetes was performed by
logistic regression. A P-value and odds-ratio were calculated for all
variants, applying an additive model. Furthermore, we analysed
the variants using the same models as in the original work by
Gaulton et al. [2]. All studies were performed with and without
adjusting for sex, age and BMI. Combined analyses of the present
and previous studies were performed by fixed-effect, additive-
models inverse variance-weighted meta-analysis. To test quanti-
tative traits for differences between genotype groups a general
linear model was used, applying additive models for each variant
and including adjustments for sex and age (for waist, waist-to-hip
ratio and BMI) or age, sex and BMI (all other traits). All analyses
were performed by RGui version 2.8.0 [12], and P-values below a
Bonferroni corrected (9 SNPs) threshold of 0.05/9=0.0056 were
considered significant. Therefore, given the multiple quantitative
phenotypes tested the analyses of diabetes-related intermediary
traits are merely explorative. Homogeneity between studies was
tested using the Mantel–Haenszel method with a generalised
linear model. All meta-analyses were performed using an additive
model.
Statistical power in case-control settings and meta-analyses was
determined using the CaTS power calculator version 0.0.2. The
prevalence of type 2 diabetes was estimated as 6%, providing 94%
statistical power to detect associations with type 2 diabetes in the
Danish study population and more than 99% in the meta-analyses,
for a variant with a minor allele frequency of 10% and with a
relative risk of 1.15.
Results
Association with type 2 diabetes
Each of the nine variants was analysed in a case-control study of
type 2 diabetes including 3,612 Danish cases and 4,973 control
subjects (Table 1). In order to replicate the previous findings by
Gaulton et al., we used the same model for each variant in the
case-control studies. Results for the additive models are also
reported for all variants (Table 1). None of the nine investigated
variants were significantly associated with type 2 diabetes after
correction for multiple testing (all P.0.0056). However, for all
nine variants the type 2 diabetes risk was non-significantly
increased for the same allele as previously reported (Table 1).
To further investigate the impact of the variants on type 2
diabetes risk, we performed combined analyses with data from
DIAGRAM+ Consortium in relation to type 2 diabetes (8,130
cases and 38,987 control subjects) [9]. The meta-analysis included
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There were no heterogeneity between the study populations
(p=0.09–1.0) using the Mantel–Haenszel method with a gener-
alised linear model. Applying an additive genetic model one of the
nine variants, the minor G-allele of TP53 rs1042522 was
associated with type 2 diabetes in the combined analysis of all
data: OR=1.06 95% CI 1.02–1.11 p=0.0032). (Figure 1).
Two of the remaining nine variants showed nominal association
with type 2 diabetes in the meta-analyses: ENPP1 rs2021966
(OR=1.05, 95% CI 1.01–1.10, P=0.012), and ENPP1 rs5400
(OR 1.07 95% CI 1.01–1.12 P=0.011).
Analyses of quantitative metabolic traits
We investigated the relationship of the nine variants with
quantitative diabetes-related metabolic traits in the Inter99 cohort
of 5,772 treatment-naive individuals. Applying an additive genetic
model the minor diabetes-associated G-allele of the TP53
rs1042522 showed nominal association with higher levels of
fasting plasma glucose (P=0.03) (Table 2). In addition, the G-
allele of ENPP1 rs858341 was associated with higher plasma
glucose at 30 min. post OGTT (P=0.0022) and a larger area
under the plasma glucose curve during the OGTT (P=0.0022).
Several other variants showed sporadic nominal associations
with the investigated traits (Tables S3, S4, S5, S6, S7, S8, S9, S10).
Furthermore, all variants were analysed using the same genetic
model as in the primary study, but none of the variants gave
stronger association with the quantitative traits.
Discussion
In the present study we evaluated the evidence for association
with type 2 diabetes for the nine most significantly associated novel
Table 1. Type 2 diabetes association for nine gene variants as listed below and which were genotyped in 3,612 type 2 diabetes
cases and 4,973 control individuals with normal glucose tolerance.
SNP Gene symbol Risk/non risk allele
Risk allele
frequency Model* P value Odds ratio (95% CI) P value Additive
rs2021966 ENPP1 A/G 0.53 REC 0.0097 1.15 (1.03–1.28) 0.015
rs858341 ENPP1 G/A 0.38 REC 0.24 1.05 (0.95–1.22) 0.15
rs4843165 FOXC2 C/T 0.73 ADD 0.76 1.01 (0.94–1.08) 0.76
rs1882095 NRF1 T/C 0.36 DOM 0.15 1.07 (0.98–1.17) 0.26
rs4740283 RAPGEF1 G/A 0.14 REC 0.69 1.08 (0.78–1.49) 0.41
rs10513684 SLC2A2 C/T 0.94 ADD 0.37 1.06 (0.93–1.23) 0.37
rs5400 SLC2A2 G/A 0.87 ADD 0.17 1.06 (0.97–1.16) 0.17
rs222852 SLC2A4 A/G 0.60 ADD 0.45 1.02 (0.96–1.09) 0.45
rs1042522 TP53 G/C 0.27 ADD 0.094 1.06 (0.99–1.14) 0.094
P-value and odds ratio were calculated assuming the same genetic model as used in the study by Gaulton et al. [Gaulton2008] (REC=recessive, ADD=additive and
DOM=dominant) and assuming additive model for all studies. Data are adjustet for sex age and BMI.
doi:10.1371/journal.pone.0015813.t001
Figure 1. Estimated odd ratio (95% CIs) of present and previously reported associations of the G-allele of TP53 rs1042522 with type
2 diabetes when analysed according to an additive genetic model (n=55,521). No heterogeneity between studies was observed (P=0.91).
Numbers in square brackets designate numbers of type 2 diabetic patients and control subjects, respectively.
doi:10.1371/journal.pone.0015813.g001
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None of them were associated with type diabetes in the Danish
study samples. However, in the meta-analyses of 55,521
Europeans TP53 rs1042522 remained significantly associated with
type 2 diabetes after correction for multiple testing. Thus, TP53
rs1042522 which is a non-synonymous amino acid substitution
(Arg72Pro), showed a 6% increase in prevalence of type 2 diabetes
per minor allele suggesting that this amino acid polymorphism
may be a novel type 2 diabetes susceptibility variant. Furthermore,
quantitative trait analysis in the Danish Inter99 showed a nominal
association with increased fasting plasma glucose levels during an
OGTT in carriers of the minor diabetogenic Arg-variant.
TP53 encodes the tumor suppressor protein p53, which is
known to be involved in cell-cycle control, apoptosis and
maintenance of genetic stability, thereby protecting the organism
from cellular damage [13]. P53 is expressed in all tissues, but at
very low levels under normal conditions. It is also expressed in the
pancreas and Arg72Pro which is located in the putative SH3
binding domain of p53 is by applying PolyPhen2H [14] predicted
to have a probably damaging impact on the structure of the
protein. Similarly, it has been shown, that the Arg72 variant
increases p53 ability to induce apoptosis whereas the Pro-encoding
allele exhibits a lower apoptotic potential [15]. An increased
apoptotic rate of the pancreatic beta-cells might lead to an
impairment of insulin secretion and possibly to an elevation of
plasma glucose. This hypothesis was, however, not supported by
the quantitative studies, since we did not find decreased serum
insulin levels during an OGTT. Still, we do not have sufficient
statistical power to detect low-impact genetic effects. Since
rs1042522 is not in high LD with other HapMap-genotyped
variants in the TP53 region, the Arg72Pro variant possibly
represents the diabetogenic variant in this locus. In 2010 a variant
(rs1799941) in SHBG, which is very close to TP53 (,40kb),
showed association with type 2 diabetes [16,17]. We found no
linkage in our study population between rs1042522 and rs1799941
(r
2=0.01), so we believe that these associations with type 2
diabetes represents independent signals. The Arg72 polymorphism
has previously been reported to associate with increased risk of
several forms of cancers [18–20].
The DIAGRAM+ Consortium data used in the combined
meta-analysis include the FUSION study on which the initial
report was based [2]. We were not technically able to exclude
these data from the meta-analysis which may therefore be
somewhat biased. Yet, given the fact that FUSION data are a
minor part of the meta-analysis and that effect estimates of Danish
and DIAGRAM+ data are virtually similar (OR 1.060 and 1.065,
respectively) we argue that the current analyses are robust. We
were only able to perform additive analyses when using
DIAGRAM+ data. We could not make a complete replication
of the primary findings according to genetic model, and there is a
possibility that this could have strengthened the association with
type 2 diabetes for the investigated variants.
Table 2. Anthropometric and metabolic characteristics of 5,772 middle-aged treatment-naive Danish Inter99 participants stratified
according to TP53 rs1042522 genotype.
TP53 rs1042522 CC CG GG P
n (men/women) 3064 (1518/1546) 2283 (1137/1146) 425 (219/206)
Age (years) 46684 6 684 6 68
BMI (kg/m
2) 26.264.6 26.164.5 26.364.5 0.6
Waist-to-hip ratio 0.8660.09 0.8560.09 0.8660.09 0.6
Waist (cm) 87613 86613 87613 0.3
Plasma glucose
Fasting (mmol/l) 5.560.8 5.560.8 5.661.2 0.03
30-min post-OGTT (mmol/l) 8.761.9 8.761.9 8.862 0.6
120-min post-OGTT (mmol/l) 6.262.1 6.262.1 6.562.4 0.09
Post-OGTT AUC (min?mmol/l) 2206134 2206137 2296139 0.5
Serum insulin
Fasting (pmol/l) 43628 41627 44631 0.7
30-min post-OGTT (pmol/l) 2906179 2906187 2986200 0.6
120-min post-OGTT (pmol/l) 2176216 2136202 2376238 0.06
Post-OGTT AUC (min?pmol/l) 22839615921 22685615451 24474618572 0.1
HOMA-IR (mmol/l?pmol/l) 10.768.1 10.367.6 11.469.7 1
Insulinogenic index (pmol6pmol
21)2 9 619 29620 30620 0.6
BIGTT-SI 9.2649 . 3 648 . 9 64 0.8
BIGTT-AIR 186161099 18076973 191961424 0.7
Fasting serum lipids
Triglyceride (mmol/l) 1.3611 . 4 61.7 1.461.2 0.1
Total cholesterol (mmol/l) 5.561.1 5.561.1 5.561.1 0.7
HDL-cholesterol (mmol/l) 1.460.4 1.460.4 1.460.4 0.4
Data are mean +/2 standard deviation. Values of serum insulin, values derived from insulin variables, and values of serum triglyceride were logarithmically transformed
before statistical analysis. Calculated P values were adjusted for age, sex, and for BMI (except BMI, waist-to-hip and waist), and were calculated assuming an additive
model. HOMA-IR was calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) and divided by 22.5. AUC, area under the curve.
doi:10.1371/journal.pone.0015813.t002
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impact type 2 diabetes variants; however current data do not
support this notion and substantial sample sizes are needed to
clarify a possible association.
The strongest impact on type 2 diabetes when exclusively
analysing the Danish data was found for the ENPP1 rs2021966
variant (OR=1.15 95% CI 1.03–1.28, P=0.015). After correction
for multiple testing this variant was, however, not associated with
type 2 diabetes in the present meta-analysis including 55,521
individuals (OR=1.05, 1.01–1.1, P=0.012). Variation in ENPP1
has previously been associated with obesity, type 2 diabetes and
insulin resistance [21,22]. Interestingly, the minor Q allele of a
K121Q (lysine to glutamine) variant (rs1044498) in ENPP1 has
been shown to influence the function of the protein by inhibiting
insulin signalling by reducing receptor function and subsequent
downstream signalling more effectively than the major K allele
[22]. A meta-analysis of more than 40.000 individuals showed that
ENPP1 K121Q increases risk of type 2 diabetes under a recessive
model; an effect that may be modulated by BMI [23]. There is low
linkage disequilibrium between rs1044498) in ENPP1 and the two
ENPP1 related variants investigated in the present study (r
2,0.3
and D9,0.6 in Inter99).Because of the low impact on type 2
diabetes, and therefore presumably low impact on intermediary
phenotypes for these ENPP1 intronic variants, we need larger well-
characterised study populations to clarify their potential underly-
ing metabolic influence.
In conclusion, we demonstrate that TP53 rs1042522 is
associated with type 2 diabetes in a meta-analysis of 55,521
Europeans suggesting that TP53 may be a novel type 2 diabetes
susceptibility locus.
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